How Roche ADC Deal At Hansoh Pharmaceutical Group (SEHK:3692) Has Changed Its Investment Story

Simply Wall St.10-25

Hansoh Pharmaceutical Group reported that its subsidiaries entered a collaboration and license agreement with Roche covering multiple Antibody Drug Conjugate programs, with Hansoh receiving an upfront...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2678700184?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice2-card/1788952923351","is_english":true,"pubTime":"2026-10-25 13:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2678700184","market":"hk","top_or_hot":-1,"title":"How Roche ADC Deal At Hansoh Pharmaceutical Group (SEHK:3692) Has Changed Its Investment Story","media":"Simply Wall St.","content":"<div>\n<p>Hansoh Pharmaceutical Group reported that its subsidiaries entered a collaboration and license agreement with Roche covering multiple Antibody Drug Conjugate programs, with Hansoh receiving an upfront...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/how-roche-adc-deal-at-hansoh-pharmaceutical-group-sehk3692-h\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Roche ADC Deal At Hansoh Pharmaceutical Group (SEHK:3692) Has Changed Its Investment Story</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Roche ADC Deal At Hansoh Pharmaceutical Group (SEHK:3692) Has Changed Its Investment Story\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-25 13:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/how-roche-adc-deal-at-hansoh-pharmaceutical-group-sehk3692-h><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hansoh Pharmaceutical Group reported that its subsidiaries entered a collaboration and license agreement with Roche covering multiple Antibody Drug Conjugate programs, with Hansoh receiving an upfront...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/how-roche-adc-deal-at-hansoh-pharmaceutical-group-sehk3692-h\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/how-roche-adc-deal-at-hansoh-pharmaceutical-group-sehk3692-h","article_id":"2678700184","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice2-card/1788952923351"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/how-roche-adc-deal-at-hansoh-pharmaceutical-group-sehk3692-h","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2678700184","pubTimestamp":1792906541,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Hansoh Pharmaceutical Group reported that its subsidiaries entered a collaboration and license agreement with Roche covering multiple Antibody Drug Conjugate programs, with Hansoh receiving an upfront US$400 million payment, a US$110 million first anniversary payment, potential milestone payments above US$15b, and retaining commercialization rights in the Chinese Mainland, Hong Kong, Macau and Taiwan.\nThe structure of the Roche agreement underscores Hansoh Pharmaceutical Group's push to...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1589":"北水核心资产","BK1191":"制药","BK1583":"高瓴概念","03692":"翰森制药"},"translate_title":"罗氏收购豪森制药集团（SEHK:3692）的 ADC 交易如何改变其投资故事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9},"content_text":"Hansoh Pharmaceutical Group reported that its subsidiaries entered a collaboration and license agreement with Roche covering multiple Antibody Drug Conjugate programs, with Hansoh receiving an upfront US$400 million payment, a US$110 million first anniversary payment, potential milestone payments above US$15b, and retaining commercialization rights in the Chinese Mainland, Hong Kong, Macau and Taiwan. The structure of the Roche agreement underscores Hansoh Pharmaceutical Group's push to monetize its ADC platform globally while keeping long term product ownership and commercial upside in its home markets. The focus now shifts to how Hansoh Pharmaceutical Group's investment narrative could evolve given this large ADC collaboration and licensing income stream.  Spot 124 healthcare AI stocks that, like Hansoh Pharmaceutical Group, are building drug platforms aimed at reshaping how complex diseases are treated.\nAdvertisementWhat Is Hansoh Pharmaceutical Group's Investment Narrative? To own Hansoh Pharmaceutical Group, you need to believe its mix of China focused commercial drugs and higher risk R&D can keep translating into real cash earnings, not just accounting profit. The Roche ADC alliance and potential US$15b milestones put execution on complex biologics front and center. In the near term, the US$400m upfront and US$110m first anniversary payments ease funding pressure on trials, but they also raise the bar on delivery from Phase Ia through global handoff. On the small molecule side, the resubmitted EU filing for Aumolertinib gives you a clear operational catalyst, since EMA validation means the review clock is running. In the short term, attention sits on regulatory progress, pricing power in China, and how much of Hansoh Pharmaceutical Group’s 42% net margin profile is tied to non cash items and a P/E of 25.5x that already prices in a fair amount of execution. That said, one issue does cut against the clean headline story once you look closely at how those earnings are built and... There's only one way to know the right time to buy, sell or hold Hansoh Pharmaceutical Group. Head to Simply Wall St's company report for the latest analysis of Hansoh Pharmaceutical Group's Fair Value. SEHK:3692 1-Year Stock Price Chart Exploring Other Perspectives The Simply Wall St Community only has two fair value estimates for Hansoh Pharmaceutical Group, clustered tightly between about 48.54 and 50.71. This leaves plenty of room for disagreement once the Roche ADC deal and Aumolertinib’s EMA review filter through. Treat this as a starting point and explore more viewpoints before forming a conviction. Explore another Hansoh Pharmaceutical Group fair value estimate, including one that suggests as much as 54% upside from the current price. Form Your Own Verdict Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.  A great starting point for your Hansoh Pharmaceutical Group research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision. See our latest analysis for Hansoh Pharmaceutical Group. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Hansoh Pharmaceutical Group's overall financial health at a glance.  Looking For More Investment Ideas Beyond Hansoh Pharmaceutical Group? If Hansoh Pharmaceutical Group has sharpened your focus on where capital could work harder, it can help to line it up against a wider set of opportunities using structured screens rather than gut feel alone.  For income focused portfolios that still care about resilience, scan a curated group of 225 dividend fortresses that aim to combine meaningful yield with balance sheet strength. If capital preservation matters as much as upside, start with 222 resilient stocks with low risk scores and narrow in on businesses scoring well on stability and financial robustness. For investors hunting underfollowed opportunities with solid fundamentals, widen the search through 612 high quality undiscovered gems that may not yet be widely researched.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Hansoh Pharmaceutical Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2678700184","isCrawlerRequest":true}